ETOSHINE 90MG TABLET 15'S

It is important to consult a healthcare professional before combining ETOSHINE 90MG TABLET 15'S with other pain medications, as they may interact and increase the risk of side effects.

Consumption of alcohol should be avoided or limited while taking ETOSHINE 90MG TABLET 15'S, as it may increase the risk of stomach bleeding and other gastrointestinal side effects.

ETOSHINE 90MG TABLET 15'S's onset of action varies, but some individuals may experience relief from pain and inflammation within a few hours to a few days of starting treatment.

ETOSHINE 90MG TABLET 15'S is contraindicated during pregnancy, especially during the third trimester, as it may harm the unborn baby. Consult a healthcare professional for alternative options if you are pregnant or planning to become pregnant.

Drowsiness is not a common side effect of ETOSHINE 90MG TABLET 15'S. However, it may cause dizziness in some individuals. Exercise caution while performing activities that require alertness until you know how ETOSHINE 90MG TABLET 15'S affects you.

ETOSHINE 90MG TABLET 15'S can be taken with or without food. However, taking it with food may help reduce the risk of stomach upset.

If you miss a dose of ETOSHINE 90MG TABLET 15'S, take it as soon as you remember. However, if it is close to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not double the dose to make up for a missed one.

ETOSHINE 90MG TABLET 15'S can be prescribed for long-term treatment, but the duration of use should be determined by a healthcare professional based on the individual's condition and response to treatment. Regular check-ups and monitoring may be required to evaluate its ongoing benefits and potential side effects.

ETOSHINE 90MG is used to relieve pain and inflammation in conditions like osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It is also prescribed for short-term pain relief in conditions such as dental or post-surgical pain.

ETOSHINE 90MG should be taken as per your doctor's prescription. Long-term use may increase the risk of heart and stomach-related side effects, so regular monitoring is advised.

Etoshine is a brand of the medicine etoricoxib, which belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs) known as selective COX-2 inhibitors. It is used to relieve pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis, and certain types of acute musculoskeletal pain. The active ingredient, etoricoxib, works by selectively inhibiting the cyclo-oxygenase-2 (COX-2) enzyme, thereby reducing the production of prostaglandins that cause pain and swelling.

Etoshine is commonly prescribed for the symptomatic treatment of pain and inflammation in chronic joint disorders such as osteoarthritis and rheumatoid arthritis, as well as in ankylosing spondylitis. It may also be used for short-term management of acute pain, including acute gouty arthritis and certain musculoskeletal conditions, when a doctor considers a COX-2 selective NSAID appropriate. It is intended to improve pain control, mobility, and overall comfort but does not cure the underlying disease.

Etoshine contains etoricoxib, which selectively inhibits the COX-2 enzyme involved in the synthesis of prostaglandins at sites of inflammation. Prostaglandins are chemical mediators that contribute to pain, swelling, and redness. By reducing prostaglandin production, Etoshine decreases inflammatory responses and alleviates pain. Because it has minimal effect on COX-1 at recommended doses, it may have a lower risk of causing certain gastrointestinal side effects compared with some traditional NSAIDs, although this risk is not completely eliminated.

Long-term use of Etoshine must be carefully evaluated by a healthcare professional. While it may be prescribed for chronic conditions such as osteoarthritis or rheumatoid arthritis, prolonged use of etoricoxib is associated with potential risks, including increased blood pressure, cardiovascular events (such as heart attack or stroke), kidney impairment, and gastrointestinal complications. The general principle is to use the lowest effective dose for the shortest duration necessary to control symptoms, with regular medical review and monitoring of blood pressure, kidney function, and overall cardiovascular risk.

Etoshine is a prescription-only medicine and should not be used for self-medication. Because etoricoxib can have significant side effects and interactions, and because the appropriate dose and duration depend on the individual’s medical history and risk factors, it must be prescribed and supervised by a qualified healthcare professional. Patients should not start, stop, or change the dose of Etoshine on their own and should not share this medicine with others.

Common side effects of Etoshine may include headache, dizziness, heartburn, indigestion, abdominal pain, nausea, diarrhea, constipation, flatulence, swelling of the ankles or feet (peripheral edema), increased blood pressure, and fatigue. Some patients may also experience mild skin rashes or flushing. These effects are usually mild to moderate and may improve as the body adjusts to the medicine, but persistent or troublesome symptoms should be discussed with a doctor.

Serious side effects, although less common, require immediate medical attention. These include chest pain, shortness of breath, sudden weakness or difficulty speaking (possible signs of heart attack or stroke), severe abdominal pain, black or bloody stools, vomiting blood or material that looks like coffee grounds (signs of gastrointestinal bleeding), marked swelling or rapid weight gain, reduced urine output (possible kidney problems), yellowing of the skin or eyes, dark urine (possible liver injury), severe skin reactions with blistering or peeling, and any signs of severe allergic reaction such as facial swelling, difficulty breathing, or widespread rash.

Etoshine is generally contraindicated in patients with known hypersensitivity to etoricoxib or any component of the formulation, those with active peptic ulcer or gastrointestinal bleeding, severe liver impairment, significant kidney dysfunction not under specialist supervision, established ischemic heart disease, peripheral arterial disease, cerebrovascular disease (such as prior stroke), or moderate to severe heart failure. It is also usually avoided in patients with uncontrolled hypertension and in those with a history of serious allergic reactions to other NSAIDs. A doctor will assess individual risks before prescribing.

Etoshine should not routinely be combined with other NSAIDs, including over-the-counter ibuprofen, diclofenac, or high-dose aspirin, because this can increase the risk of gastrointestinal bleeding, kidney damage, and other adverse effects without providing proportional additional benefit. Low-dose aspirin prescribed for cardiovascular protection may sometimes be continued, but this combination can still raise gastrointestinal risk and must be managed by a doctor. Before taking any additional painkillers, including herbal or over-the-counter products, patients should consult their healthcare provider.

If a dose of Etoshine is missed, it should be taken as soon as the patient remembers, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one, as this may increase the risk of side effects. If multiple doses are missed or there is uncertainty about how to proceed, the patient should seek advice from their prescribing doctor or pharmacist.

Etoshine, like other COX-2 selective NSAIDs, can lead to fluid retention and may increase blood pressure. In some patients, especially those with pre-existing cardiovascular disease or risk factors such as hypertension, diabetes, high cholesterol, or smoking, it may increase the risk of serious cardiovascular events, including heart attack and stroke. Blood pressure should be monitored regularly during treatment, particularly in the early weeks and in patients on long-term therapy. Any new or worsening chest pain, shortness of breath, or neurological symptoms should be reported immediately.